Skip to Content

Generic Duavee Availability

Duavee is a brand name of bazedoxifene/conjugated estrogens, approved by the FDA in the following formulation(s):

DUAVEE (bazedoxifene acetate; estrogens, conjugated - tablet;oral)

  • Manufacturer: WYETH PHARMS PFIZER
    Approval date: October 3, 2013
    Strength(s): EQ 20MG BASE;0.45MG [RLD]

Has a generic version of Duavee been approved?

No. There is currently no therapeutically equivalent version of Duavee available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Duavee. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
    Patent 5,998,402
    Issued: December 7, 1999
    Inventor(s): Miller; Chris P. & Collini; Michael D. & Tran; Bach D. & Santilli; Arthur A.
    Assignee(s): American Home Products Corporation
    The present invention relates to new 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole compounds which are useful as estrogenic agents, as well as pharmaceutical compositions and methods of treatment utilizing these compounds, which have the general structures below: ##STR1##
    Patent expiration dates:
    • April 4, 2017
      ✓ 
      Patent use: PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
    Patent 6,479,535
    Issued: November 12, 2002
    Inventor(s): James Harrison; Pickar & Barry Samuel; Komm
    Assignee(s): Wyeth
    The present invention relates to new formulations containing one or more estrogens and 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole compounds which are useful as estrogenic agents, as well as pharmaceutical compositions and methods of treatment utilizing these compounds, which have the general structures below:
    Patent expiration dates:
    • May 6, 2019
      ✓ 
      Patent use: TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE
      ✓ 
      Drug product
    • May 6, 2019
      ✓ 
      Patent use: PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
      ✓ 
      Drug product
  • 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
    Patent 7,138,392
    Issued: November 21, 2006
    Inventor(s): Miller; Chris P. & Collini; Michael D.
    The present invention relates to new 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole compounds having the general structures below: or which are useful in treating or preventing bone loss.
    Patent expiration dates:
    • April 4, 2017
      ✓ 
      Patent use: PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Crystalline polymorph of bazedoxifene acetate
    Patent 7,683,051
    Issued: March 23, 2010
    Inventor(s): Demerson; Christopher & Iera; Silvio & Ali; Kadum A.
    Assignee(s): Wyeth
    The present invention is directed to a crystalline polymorph of bazedoxifene acetate, compositions containing the same, preparations thereof, and uses thereof.
    Patent expiration dates:
    • March 10, 2027
      ✓ 
      Patent use: TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • March 10, 2027
      ✓ 
      Patent use: PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole and estrogen formulations
    Patent 8,815,934
    Issued: August 26, 2014
    Assignee(s): Wyeth LLC
    The present invention relates to new formulations containing one or more estrogens and 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole compounds which are useful as estrogenic agents, as well as pharmaceutical compositions and methods of treatment utilizing these compounds, which have the general structures below:
    Patent expiration dates:
    • May 6, 2019
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • October 3, 2016 - NEW PRODUCT

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide